Twice-weekly intravenous treatment of pancreatic cancer with atrial natriuretic peptide and vessel dilator
Lenz, A.; Sun, Y.; Eichelbaum, E.J.; Skelton, W.P.; Pi, G.; Vesely, D.L.
In Vivo 24(2): 125-129
2010
ISSN/ISBN: 0258-851X PMID: 20363982 Document Number: 641235
Atrial natriuretic peptide (ANP) and vessel dilator eliminate 80% and 33% of human pancreatic adenocarcinomas growing in athymic mice when given subcutaneously for 28 days via osmotic pumps. To determine if similar beneficial effects can be obtained by ANP and vessel dilator on a bi-weekly basis, bolus infusion via vascular ports bi-weekly for 4 weeks was given to athymic mice bearing human pancreatic adenocarcinomas. Vessel dilator and ANP (each at 100 microM) (n=6 for each) resulted in a 33% (p<0.01) and 17% (p<0.05) elimination of human pancreatic adenocarcinomas, respectively, while the tumor volume increased 64-fold (p<0.001) in the placebo-treated mice (n=12). During the 4 weeks of treatment, the growth velocity decreased 92% and 68% with vessel dilator and ANP, respectively, compared to untreated mice. Biweekly vessel dilator and ANP both eliminate some human pancreatic adenocarcinomas in athymic mice.